Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04707573 · ClinicalTrials.gov registry record · Phase 2
Study to Assess the Safety and Pharmacokinetics of AKB-6548 in Participants With Chronic Kidney Disease (CKD), Stages 3 and 4
A Phase 2 study, sponsored by Akebia Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
NCT04707573 is a Phase 2 study that has completed, run by Akebia Therapeutics. The registered enrollment target is 22 participants.
The verdict
NCT04707573, a Phase 2 study, has completed, sponsored by Akebia Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
Study Summary
This study was conducted to assess the pharmacokinetic (PK) profile, safety, and tolerability in participants with Stage 3 and 4 Chronic Kidney Disease (CKD) following a single oral dose of Vadadustat.
Interventions
- DRUG Vadadustat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2010-07-08 |
| Est. Completion | 2010-09-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04707573
The ClinicalTrials.gov registry entry for NCT04707573 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Akebia Therapeutics, which has 24 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Vadadustat is the first listed.
NCT04707573 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04707573 about?
NCT04707573 is a clinical study titled "Study to Assess the Safety and Pharmacokinetics of AKB-6548 in Participants With Chronic Kidney Disease (CKD), Stages 3 and 4". This study was conducted to assess the pharmacokinetic (PK) profile, safety, and tolerability in participants with Stage 3 and 4 Chronic Kidney Disease (CKD) following a single oral dose of Vadadustat.
What is the current status of trial NCT04707573?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2010-07-08. Estimated completion is 2010-09-24.
What interventions are being tested in trial NCT04707573?
The interventions under investigation include: Vadadustat (DRUG).
Who is sponsoring clinical trial NCT04707573?
This trial is sponsored by Akebia Therapeutics, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.